TRCT
DOVA

Tower Research Capital (TRC)’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Tower Research Capital (TRC)’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,876
Closed -$52K – 4865
2019
Q3 		$52K Buy
1,876
+1,856
+9,280% +$30.1K ﹤0.01% 1781
2019
Q2 		$0 Sell
20
-1,563
-99% -$14.9K ﹤0.01% 4676
2019
Q1 		$14K Sell
1,583
-19,030
-92% -$154K ﹤0.01% 2508
2018
Q4 		$156K Buy
20,613
+13,083
+174% +$211K 0.01% 777
2018
Q3 		$158K Buy
+7,530
New +$179K 0.01% 1112
2018
Q2 		– Sell
-2,210
Closed -$60K – 4327
2018
Q1 		$60K Buy
+2,210
New +$66.1K 0.01% 1581
2017
Q4 		– Sell
-961
Closed -$23K – 4313
2017
Q3 		$23K Buy
961
+661
+220% +$15.7K ﹤0.01% 2663
2017
Q2 		$7K Buy
+300
New +$6.32K ﹤0.01% 1854

Tower Research Capital (TRC)'s DOVA Position: Q4 2019 in Review

Tower Research Capital (TRC) sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2019, closing a stake of 1,876 shares — an estimated $52K sold.

Tower Research Capital (TRC) first reported a position in DOVA in Q2 2017 and held it in 8 quarters. The position peaked at $158K in Q3 2018. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

  • Tower Research Capital (TRC) reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,876 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $52K.
  • Tower Research Capital (TRC) first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 8 quarters.
  • Tower Research Capital (TRC)'s Dova Pharmaceuticals, Inc. Common Stock position peaked at $158K in Q3 2018.
  • 0 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2019, filed 7 Feb 2020.